NASDAQ
No price data available for this timeframe.
ANI Pharmaceuticals, Inc. (ANIP) has a consensus Buy rating from 10 analysts with an average price target of $124.00, representing +49.4% upside from the current price of $83.00.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Jan 16, 2026 | Vamil Divan | Guggenheim | $124.00 | $85.29 | +45.39% |
| Oct 9, 2025 | Unknown | Truist Financial | $90.00 | $91.63 | -1.78% |
| Sep 17, 2025 | Brandon Folkes | H.C. Wainwright | $121.00 | $95.36 | +26.89% |
| Sep 8, 2025 | Vamil Divan | Guggenheim | $114.00 | $95.20 |
Jan 16, 2026 | Maintained | Guggenheim | Buy | Buy |
Nov 10, 2025 | Maintained | Guggenheim | Buy | Buy |
Oct 9, 2025 | Maintained | Truist Securities | Hold | Hold |
Sep 24, 2025 | Maintained | JP Morgan | Overweight | Overweight |
Sep 17, 2025 | Maintained | HC Wainwright & Co. | Buy | Buy |
| +19.75% |
| Aug 8, 2025 | David Amsellem | Piper Sandler | $94.00 | $81.13 | +15.86% |